Oppenheimer Assumes OvaScience (OVAS) at Perform

Oppenheimer assumes coverage on OvaScience (NASDAQ: OVAS) with a Perform rating.

Analyst Derek Archila commented, "We are assuming coverage of OVAS and maintain our Perform rating largely due to the lack of revenue visibility in the near-to-medium term. Over the next 12 months, we expect investors to focus on: 1) management's update from the FDA regarding a regulatory pathway for AUGMENT in the US in 4Q16; 2) a go or no-go decision on the company's OvaPrime treatment in 4Q16; and 3) top line results from the first multicenter trial for AUGMENT in the 2H17. In our view, the latter is the most important as we believe positive data from a controlled, double-blinded, randomized egg allocation study is needed for further adoption among new/existing clinics and expansion of the addressable market into a broader population of women."

For an analyst ratings summary and ratings history on OvaScience click here. For more ratings news on OvaScience click here.

Shares of OvaScience closed at $3.32 yesterday.

You May Also Be Interested In

• Golar LNG Ltd. (GLNG) PT Raised to $70 at BTIG
• Freedom Broker Double Downgrades Mosaic (MOS) to Sell
• Goldman Sachs Positive on SanDisk (SNDK): 'We expect the stock to hold its gains'